541 related articles for article (PubMed ID: 23077931)
1. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
[TBL] [Abstract][Full Text] [Related]
2. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
[TBL] [Abstract][Full Text] [Related]
3. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.
Loria P; Lonardo A; Bellentani S; Day CP; Marchesini G; Carulli N
Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):684-98. PubMed ID: 17560098
[TBL] [Abstract][Full Text] [Related]
5. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.
Adams LA; Waters OR; Knuiman MW; Elliott RR; Olynyk JK
Am J Gastroenterol; 2009 Apr; 104(4):861-7. PubMed ID: 19293782
[TBL] [Abstract][Full Text] [Related]
6. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
[TBL] [Abstract][Full Text] [Related]
7. The role of non-alcoholic fatty liver disease in cardiovascular disease.
Perseghin G
Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.
Moore JB
Proc Nutr Soc; 2010 May; 69(2):211-20. PubMed ID: 20158939
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.
Uchil D; Pipalia D; Chawla M; Patel R; Maniar S; Narayani ; Juneja A
J Assoc Physicians India; 2009 Mar; 57():201-4. PubMed ID: 19588647
[TBL] [Abstract][Full Text] [Related]
10. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
Fan JG
J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
[TBL] [Abstract][Full Text] [Related]
11. From the metabolic syndrome to NAFLD or vice versa?
Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of nonalcoholic fatty liver disease in adults.
Clark JM
J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease and hepatitis C infection.
Bondini S; Younossi ZM
Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
[TBL] [Abstract][Full Text] [Related]
14. Significant correlations between severe fatty liver and risk factors for metabolic syndrome.
Hsiao PJ; Kuo KK; Shin SJ; Yang YH; Lin WY; Yang JF; Chiu CC; Chuang WL; Tsai TR; Yu ML
J Gastroenterol Hepatol; 2007 Dec; 22(12):2118-23. PubMed ID: 18031368
[TBL] [Abstract][Full Text] [Related]
15. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
Nestel PJ; Mensink RP
Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response.
Younossi ZM; McCullough AJ
Liver Int; 2009 Mar; 29 Suppl 2():3-12. PubMed ID: 19187068
[TBL] [Abstract][Full Text] [Related]
17. Role of diet and nutritional management in non-alcoholic fatty liver disease.
Fan JG; Cao HX
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
[TBL] [Abstract][Full Text] [Related]
18. Hepatic steatosis and vascular disease.
Santoliquido A; Di Campli C; Miele L; Gabrieli ML; Forgione A; Zocco MA; Lupascu A; Di Giorgio A; Flore R; Pola P; Gasbarrini G; Gasbarrini A; Tondi P; Grieco A
Eur Rev Med Pharmacol Sci; 2005; 9(5):269-71. PubMed ID: 16231588
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease.
Lu H; Zeng L; Liang B; Shu X; Xie D
Arch Med Res; 2009 Oct; 40(7):571-5. PubMed ID: 20082871
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease.
Friis-Liby I; Aldenborg F; Jerlstad P; Rundström K; Björnsson E
Scand J Gastroenterol; 2004 Sep; 39(9):864-9. PubMed ID: 15513385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
